Stockwatch: When pharma says return to sender
This article was originally published in Scrip
Executive Summary
A steady stream of loss-making biotechnology companies reported their financial results for the last quarter of 2010 this week. The reporting of a little more, or a little less cash spent when the company has no product sales, in the cases of Cadence, Micromet Chelsea and Anadys, or on annual sales of $12m for Allos Therapeutics and $48m for Dendreon, is not likely to be a stock price moving event.